1-9 of 9
Ben L. Sanford
Close
Sort by
Journal Articles

Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study

Konstanze Döhner, MD, Christian Thiede, MD, Richard A. Larson, MD, Thomas W Prior, MD, Guido Marcucci, MD, Dan Jones, MD, Jürgen Krauter, MD, Michael Heuser, MD, Francesco Lo Coco, MD, Tiziana Ottone, PhD, Josep Nomdedeu, Sumithra J Mandrekar, PhD, Ben L. Sanford, MS, Kristine Laumann, Susan M. Geyer, PhD, Rebecca B. Klisovic, MD, Andrew Wei, MBBS, PhD FRACP, FRCPA, Jorge Sierra, Miguel A. Sanz, MD, Joseph M. Brandwein, MD FRCPC, T. M. M de Witte, MD PhD, Joop H. Jansen, Dietger Niederwieser, MD, Frederick R. Appelbaum, MD, Bruno C Medeiros, MD, Martin S. Tallman, MD, Richard F. Schlenk, MD, Arnold Ganser, MD, Hubert Serve, Gerhard Ehninger, Sergio Amadori, MD, Yuan Cheng, PhD, Celine Pallaud, PhD, Richard M. Stone, MD, Hartmut Döhner, MD, Clara D. Bloomfield, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 467.
https://doi.org/10.1182/blood.V130.Suppl_1.467.467
Published: 2017
Journal Articles

The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Richard M. Stone, MD, Sumithra J Mandrekar, PhD, Ben L. Sanford, MS, Kristine Laumann, Susan M. Geyer, PhD, Clara D. Bloomfield, MD, Konstanze Dohner, MD, Christian Thiede, MD, Guido Marcucci, MD, Francesco Lo Coco, MD, Rebecca B. Klisovic, MD, Andrew Wei, MBBS, PhD FRACP, FRCPA, Jorge Sierra, Miguel A. Sanz, MD, Joseph M. Brandwein, MD FRCPC, T. M. M de Witte, MD PhD, Dietger Niederwieser, MD, Frederick R. Appelbaum, MD, Bruno C Medeiros, MD, Martin S. Tallman, MD, Jurgen Krauter, MD, Richard F. Schlenk, MD, Arnold Ganser, MD, Hubert Serve, Gerhard Ehninger, Sergio Amadori, MD, Hartmut Dohner, MD, Richard A. Larson, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2580.
https://doi.org/10.1182/blood.V130.Suppl_1.2580.2580
Published: 2017
Journal Articles

An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Richard A. Larson, MD, Sumithra J Mandrekar, PhD, Ben L. Sanford, MS, Kristine Laumann, Susan M. Geyer, PhD, Clara D. Bloomfield, MD, Christian Thiede, MD, Thomas W Prior, MD, Konstanze Dohner, MD, Guido Marcucci, MD, Francesco Lo Coco, MD, Rebecca B. Klisovic, MD, Andrew Wei, MBBS, PhD FRACP, FRCPA, Jorge Sierra, Miguel A. Sanz, MD, Joseph M. Brandwein, MD FRCPC, T. M. M de Witte, MD PhD, Dietger Niederwieser, MD, Frederick R. Appelbaum, MD, Bruno C Medeiros, MD, Martin S. Tallman, MD, Jurgen Krauter, MD, Richard F. Schlenk, MD, Arnold Ganser, MD, Hubert Serve, Gerhard Ehninger, Sergio Amadori, MD, Hartmut Döhner, MD, Richard M. Stone, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 145.
https://doi.org/10.1182/blood.V130.Suppl_1.145.145
Published: 2017
Journal Articles

The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])

Richard M. Stone, MD, Sumithra Mandrekar, Ben L Sanford, MS, Susan Geyer, PhD, Clara D. Bloomfield, MD, Konstanze Dohner, MD, Christian Thiede, MD, Guido Marcucci, MD, Francesco Lo-Coco, Rebecca B. Klisovic, MD, Andrew Wei, MBBS, PhD, Jorge Sierra, MD PhD, Miguel A. Sanz, MD PhD, Joseph M. Brandwein, MD FRCPC, Theo de Witte, MD, Dietger Niederwieser, MD, Frederick R. Appelbaum, MD, Bruno C. Medeiros, MD, Martin S Tallman, MD, Jurgen Krauter, MD, Richard F. Schlenk, MD, Arnold Ganser, MD, Hubert Serve, Gerhard Ehninger, MD, Sergio Amadori, MD, Richard A. Larson, MD, Hartmut Dohner, MD
Journal: Blood
Blood (2015) 126 (23): 6.
https://doi.org/10.1182/blood.V126.23.6.6
Published: 2015
Journal Articles

Cytarabine, Daunorubicin and Etoposide (ADE) Chemotherapy in Acute Myeloid Leukemia (AML) Patients ≥60 Years (CALGB 9720).

Maria R. Baer, MD, Stephen L. George, PhD, Ben L. Sanford, MS, Sandra M. Bothun, BS, Krzysztof Mrozek, PhD, Kieran L. O’Loughlin, BS, Jonathan E. Kolitz, MD, Joseph O. Moore, MD, Richard M. Stone, MD, Bayard L. Powell, MD, Michael A. Caligiuri, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD
Journal: Blood
Blood (2007) 110 (11): 296.
https://doi.org/10.1182/blood.V110.11.296.296
Published: 2007
Journal Articles

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511

Clinical Trials & Observations Brief Report
Meir Wetzler, Ben L. Sanford, Joanne Kurtzberg, Divino DeOliveira, Stanley R. Frankel, Bayard L. Powell, Jonathan E. Kolitz, Clara D. Bloomfield, Richard A. Larson
Journal: Blood
Blood (2007) 109 (10): 4164–4167.
https://doi.org/10.1182/blood-2006-09-045351
Published: 2007
Includes: Supplemental data
Journal Articles

A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) in Patients with Myelodysplastic Syndrome (MDS): Cancer and Leukemia Group B Study 10105.

Pankaj Gupta, MD, Ben L. Sanford, MS, Daohai Yu, PhD, Ravi Vij, MD, David D. Hurd, MD, Olatoyosi Odenike, MD, Clara D. Bloomfield, MD, Robert P. Hasserjian, MD, Richard A. Larson, MD
Journal: Blood
Blood (2006) 108 (11): 2665.
https://doi.org/10.1182/blood.V108.11.2665.2665
Published: 2006
Journal Articles

Phase III Study of Immunotherapy with Recombinant Interleukin-2 (IL-2) Versus No Further Therapy in Acute Myeloid Leukemia (AML) Patients ≥ 60 Years in First Complete Remission (CALGB 9720).

Maria R. Baer, MD, Stephen L. George, PhD, Michael A. Caligiuri, MD, Ben L. Sanford, MS, Kieran L. O’Loughlin, MS, Krysztof Mrozek, PhD, Jonathan E. Kolitz, MD, Bayard L. Powell, MD, Joseph O. Moore, MD, Richard M. Stone, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD
Journal: Blood
Blood (2006) 108 (11): 424.
https://doi.org/10.1182/blood.V108.11.424.424
Published: 2006
Journal Articles

Effective Asparagine Depletion with Pegylated Asparaginase Results in Improved Outcomes in Adult Acute Lymphoblastic Leukemia (ALL) — Cancer and Leukemia Group B Study 9511.

Meir Wetzler, MD, Ben L. Sanford, Kouros Owzar, Joanne Kurtzberg, MD, D. DeOliveira, MD, Stanley R. Frankel, MD, Bayard L. Powell, MD, Jonathan E. Kolitz, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD
Journal: Blood
Blood (2005) 106 (11): 1825.
https://doi.org/10.1182/blood.V106.11.1825.1825
Published: 2005